Recently, the National Medical Products 奥洛格列净胶囊 (NMPA) has approved the marketing of Olozogliptin Capsules (trade name: 东泽安), a Class 1 innovative drug filed by Yichang East Sunshine Changjiang Pharmaceutical Co., Ltd.
This drug is indicated for improving glycemic control in adult patients with type 2 diabetes mellitus. Its launch offers a new treatment option for patients.
